Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In this edition of StockCharts TV‘s StockCharts in Focus, Grayson shows you how to enhance your moving averages with 4 unique charts, straight out ...
Is charity a right held by everyone or should charity be confined to private, voluntary action within a free market? David Gordon argues for the latter. ...
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading leaked, or traders and investors felt the stock market was getting so toppy that it was time to take some profits ...
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish engulfing patterns to indicate short-term distributions. He also addresses the ongoing divergence between large caps and ...
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS, buying breakouts below the 200-day moving average, upside targets for gold, and whether the $USD is ...
The socialist elites that dominate our institutions insist that private property is nothing more than a social construct held together by violence. As usual, they misunderstand that scarcity itself, which is the basis for economics, is also the basis for ...
Bob continues his feud with George Selgin, explaining why the alleged free banking period in Scotland doesn’t show that free-market banks would carry low reserve ratios. ...
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets. I have two friends; one whose birthday is June 21 and the other whose birthday is ...
Is charity a right held by everyone or should charity be confined to private, voluntary action within a free market? David Gordon argues for the latter. ...
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated in the trial, and none of them contracted HIV, signaling a potential game-changer for HIV prevention. ...